Genetic testing boosts efficacy in cancer care
Tailoring cancer therapies to fit a person's genetic makeup could spare thousands of patients from harmful side effects and save millions of dollars a year, a study shows. Treating a colorectal cancer patient with a drug called Erbitux, for example, costs more than $61,000 for a typical treatment with 24 doses, according to a study presented at the American Society of Clinical Oncology meeting. But over the past year or so, several studies have shown neither Erbitux or Vectibix works in patients with a certain genetic mutation. Giving Erbitux only to patients without the mutations would save the country up to $604 million a year, researchers said.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- IOM Identifies GME Problems, Calls for Finance Changes
- Revenue Cycles Get a Boost from Simple JPEG Files
- Healthcare Costs Start With What We Eat
- CA Fines 8 Hospitals for Medical Errors
- Handshaking Spreads Germs. Get Over It.
- Anatomy of 3 Health System Rebranding Efforts